Kemian ja bioteknologia-alan ammattitapahtuma ChemBio Finland korostaa ohjelmasisällöissään kestävää kasvua sekä kemian ja bioteknologian tarjoamia ratkaisuja hyvinvointiin. ChemBio Finland järjestetään Helsingissä Messukeskuksessa 27.–28.4.2021.

Applied Genetic Technologies Corporation (AGTC), Blueprint Genetics, and Foundation Fighting Blindness, announce today that AGTC, a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, will join the My Retina Tracker® Program as a new scientific collaborator to enhance development of  its investigational gene therapies for inherited retinal diseases (IRDs). The My Retina Tracker® Program, a collaboration between Blueprint Genetics, Foundation Fighting Blindness and InformedDNA, is an open access, no-cost program that offers individuals with IRDs easy access to high-quality genetic diagnostics and genetic counseling. This program has become one of the largest volume genetic testing initiatives for IRDs globally.

Together, Quest Diagnostics, the world’s leading provider of diagnostic information services, and Blueprint Genetics will broaden access to actionable insights in genetic and rare diseases, improving patient care and pharmaceutical drug research and development. Financial terms of the transaction were not disclosed.